Pharmacological Potential of Endothelin Receptors Agonists and Antagonists
Endothelins are potent predominantly vasoconstricting agents that act as local autocrine and paracrine mediators. Endothelin-1 is the most potent and sustained vasoconstrictor and pressor substance yet identified. Abnormalities of the endothelin system occur in a range of diseases associated with va...
Ausführliche Beschreibung
Autor*in: |
Jiří Patočka [verfasserIn] Vladimír Měrka [verfasserIn] Vratislav Hrdina [verfasserIn] Radomír Hrdina [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2005 |
---|
Schlagwörter: |
---|
Übergeordnetes Werk: |
In: Acta Medica - Karolinum Press, 2004, 48(2005), 2, Seite 67-73 |
---|---|
Übergeordnetes Werk: |
volume:48 ; year:2005 ; number:2 ; pages:67-73 |
Links: |
Link aufrufen |
---|
DOI / URN: |
10.14712/18059694.2018.34 |
---|
Katalog-ID: |
DOAJ039212548 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | DOAJ039212548 | ||
003 | DE-627 | ||
005 | 20230308030026.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230227s2005 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.14712/18059694.2018.34 |2 doi | |
035 | |a (DE-627)DOAJ039212548 | ||
035 | |a (DE-599)DOAJe6114750a1dc45e2b0ef522e39c826f7 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 0 | |a Jiří Patočka |e verfasserin |4 aut | |
245 | 1 | 0 | |a Pharmacological Potential of Endothelin Receptors Agonists and Antagonists |
264 | 1 | |c 2005 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Endothelins are potent predominantly vasoconstricting agents that act as local autocrine and paracrine mediators. Endothelin-1 is the most potent and sustained vasoconstrictor and pressor substance yet identified. Abnormalities of the endothelin system occur in a range of diseases associated with vasoconstriction, vasospasm, and vascular hypertrophy. ET receptor antagonists were until recently regarded as drugs of great promise in patients with congestive heart failure, pulmonary hypertension and others. The aim of this article is a survey of compounds that affect the endothelin receptors and clinical trials with these agents. | ||
650 | 4 | |a Endothelin | |
650 | 4 | |a Endothelin receptor | |
650 | 4 | |a Endothelin receptor agonist | |
650 | 4 | |a Endothelin receptor antagonist | |
650 | 4 | |a Bosentan | |
650 | 4 | |a Pulmonary hypertension treatment | |
653 | 0 | |a Medicine | |
653 | 0 | |a R | |
700 | 0 | |a Vladimír Měrka |e verfasserin |4 aut | |
700 | 0 | |a Vratislav Hrdina |e verfasserin |4 aut | |
700 | 0 | |a Radomír Hrdina |e verfasserin |4 aut | |
773 | 0 | 8 | |i In |t Acta Medica |d Karolinum Press, 2004 |g 48(2005), 2, Seite 67-73 |w (DE-627)320418170 |w (DE-600)2002210-4 |x 18059694 |7 nnns |
773 | 1 | 8 | |g volume:48 |g year:2005 |g number:2 |g pages:67-73 |
856 | 4 | 0 | |u https://doi.org/10.14712/18059694.2018.34 |z kostenfrei |
856 | 4 | 0 | |u https://doaj.org/article/e6114750a1dc45e2b0ef522e39c826f7 |z kostenfrei |
856 | 4 | 0 | |u https://actamedica.lfhk.cuni.cz/48/2/0067/ |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/1211-4286 |y Journal toc |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/1805-9694 |y Journal toc |z kostenfrei |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_DOAJ | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_206 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4367 | ||
912 | |a GBV_ILN_4700 | ||
951 | |a AR | ||
952 | |d 48 |j 2005 |e 2 |h 67-73 |
author_variant |
j p jp v m vm v h vh r h rh |
---|---|
matchkey_str |
article:18059694:2005----::hraooiaptnilfnohlneetrao |
hierarchy_sort_str |
2005 |
publishDate |
2005 |
allfields |
10.14712/18059694.2018.34 doi (DE-627)DOAJ039212548 (DE-599)DOAJe6114750a1dc45e2b0ef522e39c826f7 DE-627 ger DE-627 rakwb eng Jiří Patočka verfasserin aut Pharmacological Potential of Endothelin Receptors Agonists and Antagonists 2005 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Endothelins are potent predominantly vasoconstricting agents that act as local autocrine and paracrine mediators. Endothelin-1 is the most potent and sustained vasoconstrictor and pressor substance yet identified. Abnormalities of the endothelin system occur in a range of diseases associated with vasoconstriction, vasospasm, and vascular hypertrophy. ET receptor antagonists were until recently regarded as drugs of great promise in patients with congestive heart failure, pulmonary hypertension and others. The aim of this article is a survey of compounds that affect the endothelin receptors and clinical trials with these agents. Endothelin Endothelin receptor Endothelin receptor agonist Endothelin receptor antagonist Bosentan Pulmonary hypertension treatment Medicine R Vladimír Měrka verfasserin aut Vratislav Hrdina verfasserin aut Radomír Hrdina verfasserin aut In Acta Medica Karolinum Press, 2004 48(2005), 2, Seite 67-73 (DE-627)320418170 (DE-600)2002210-4 18059694 nnns volume:48 year:2005 number:2 pages:67-73 https://doi.org/10.14712/18059694.2018.34 kostenfrei https://doaj.org/article/e6114750a1dc45e2b0ef522e39c826f7 kostenfrei https://actamedica.lfhk.cuni.cz/48/2/0067/ kostenfrei https://doaj.org/toc/1211-4286 Journal toc kostenfrei https://doaj.org/toc/1805-9694 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 48 2005 2 67-73 |
spelling |
10.14712/18059694.2018.34 doi (DE-627)DOAJ039212548 (DE-599)DOAJe6114750a1dc45e2b0ef522e39c826f7 DE-627 ger DE-627 rakwb eng Jiří Patočka verfasserin aut Pharmacological Potential of Endothelin Receptors Agonists and Antagonists 2005 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Endothelins are potent predominantly vasoconstricting agents that act as local autocrine and paracrine mediators. Endothelin-1 is the most potent and sustained vasoconstrictor and pressor substance yet identified. Abnormalities of the endothelin system occur in a range of diseases associated with vasoconstriction, vasospasm, and vascular hypertrophy. ET receptor antagonists were until recently regarded as drugs of great promise in patients with congestive heart failure, pulmonary hypertension and others. The aim of this article is a survey of compounds that affect the endothelin receptors and clinical trials with these agents. Endothelin Endothelin receptor Endothelin receptor agonist Endothelin receptor antagonist Bosentan Pulmonary hypertension treatment Medicine R Vladimír Měrka verfasserin aut Vratislav Hrdina verfasserin aut Radomír Hrdina verfasserin aut In Acta Medica Karolinum Press, 2004 48(2005), 2, Seite 67-73 (DE-627)320418170 (DE-600)2002210-4 18059694 nnns volume:48 year:2005 number:2 pages:67-73 https://doi.org/10.14712/18059694.2018.34 kostenfrei https://doaj.org/article/e6114750a1dc45e2b0ef522e39c826f7 kostenfrei https://actamedica.lfhk.cuni.cz/48/2/0067/ kostenfrei https://doaj.org/toc/1211-4286 Journal toc kostenfrei https://doaj.org/toc/1805-9694 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 48 2005 2 67-73 |
allfields_unstemmed |
10.14712/18059694.2018.34 doi (DE-627)DOAJ039212548 (DE-599)DOAJe6114750a1dc45e2b0ef522e39c826f7 DE-627 ger DE-627 rakwb eng Jiří Patočka verfasserin aut Pharmacological Potential of Endothelin Receptors Agonists and Antagonists 2005 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Endothelins are potent predominantly vasoconstricting agents that act as local autocrine and paracrine mediators. Endothelin-1 is the most potent and sustained vasoconstrictor and pressor substance yet identified. Abnormalities of the endothelin system occur in a range of diseases associated with vasoconstriction, vasospasm, and vascular hypertrophy. ET receptor antagonists were until recently regarded as drugs of great promise in patients with congestive heart failure, pulmonary hypertension and others. The aim of this article is a survey of compounds that affect the endothelin receptors and clinical trials with these agents. Endothelin Endothelin receptor Endothelin receptor agonist Endothelin receptor antagonist Bosentan Pulmonary hypertension treatment Medicine R Vladimír Měrka verfasserin aut Vratislav Hrdina verfasserin aut Radomír Hrdina verfasserin aut In Acta Medica Karolinum Press, 2004 48(2005), 2, Seite 67-73 (DE-627)320418170 (DE-600)2002210-4 18059694 nnns volume:48 year:2005 number:2 pages:67-73 https://doi.org/10.14712/18059694.2018.34 kostenfrei https://doaj.org/article/e6114750a1dc45e2b0ef522e39c826f7 kostenfrei https://actamedica.lfhk.cuni.cz/48/2/0067/ kostenfrei https://doaj.org/toc/1211-4286 Journal toc kostenfrei https://doaj.org/toc/1805-9694 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 48 2005 2 67-73 |
allfieldsGer |
10.14712/18059694.2018.34 doi (DE-627)DOAJ039212548 (DE-599)DOAJe6114750a1dc45e2b0ef522e39c826f7 DE-627 ger DE-627 rakwb eng Jiří Patočka verfasserin aut Pharmacological Potential of Endothelin Receptors Agonists and Antagonists 2005 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Endothelins are potent predominantly vasoconstricting agents that act as local autocrine and paracrine mediators. Endothelin-1 is the most potent and sustained vasoconstrictor and pressor substance yet identified. Abnormalities of the endothelin system occur in a range of diseases associated with vasoconstriction, vasospasm, and vascular hypertrophy. ET receptor antagonists were until recently regarded as drugs of great promise in patients with congestive heart failure, pulmonary hypertension and others. The aim of this article is a survey of compounds that affect the endothelin receptors and clinical trials with these agents. Endothelin Endothelin receptor Endothelin receptor agonist Endothelin receptor antagonist Bosentan Pulmonary hypertension treatment Medicine R Vladimír Měrka verfasserin aut Vratislav Hrdina verfasserin aut Radomír Hrdina verfasserin aut In Acta Medica Karolinum Press, 2004 48(2005), 2, Seite 67-73 (DE-627)320418170 (DE-600)2002210-4 18059694 nnns volume:48 year:2005 number:2 pages:67-73 https://doi.org/10.14712/18059694.2018.34 kostenfrei https://doaj.org/article/e6114750a1dc45e2b0ef522e39c826f7 kostenfrei https://actamedica.lfhk.cuni.cz/48/2/0067/ kostenfrei https://doaj.org/toc/1211-4286 Journal toc kostenfrei https://doaj.org/toc/1805-9694 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 48 2005 2 67-73 |
allfieldsSound |
10.14712/18059694.2018.34 doi (DE-627)DOAJ039212548 (DE-599)DOAJe6114750a1dc45e2b0ef522e39c826f7 DE-627 ger DE-627 rakwb eng Jiří Patočka verfasserin aut Pharmacological Potential of Endothelin Receptors Agonists and Antagonists 2005 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Endothelins are potent predominantly vasoconstricting agents that act as local autocrine and paracrine mediators. Endothelin-1 is the most potent and sustained vasoconstrictor and pressor substance yet identified. Abnormalities of the endothelin system occur in a range of diseases associated with vasoconstriction, vasospasm, and vascular hypertrophy. ET receptor antagonists were until recently regarded as drugs of great promise in patients with congestive heart failure, pulmonary hypertension and others. The aim of this article is a survey of compounds that affect the endothelin receptors and clinical trials with these agents. Endothelin Endothelin receptor Endothelin receptor agonist Endothelin receptor antagonist Bosentan Pulmonary hypertension treatment Medicine R Vladimír Měrka verfasserin aut Vratislav Hrdina verfasserin aut Radomír Hrdina verfasserin aut In Acta Medica Karolinum Press, 2004 48(2005), 2, Seite 67-73 (DE-627)320418170 (DE-600)2002210-4 18059694 nnns volume:48 year:2005 number:2 pages:67-73 https://doi.org/10.14712/18059694.2018.34 kostenfrei https://doaj.org/article/e6114750a1dc45e2b0ef522e39c826f7 kostenfrei https://actamedica.lfhk.cuni.cz/48/2/0067/ kostenfrei https://doaj.org/toc/1211-4286 Journal toc kostenfrei https://doaj.org/toc/1805-9694 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 48 2005 2 67-73 |
language |
English |
source |
In Acta Medica 48(2005), 2, Seite 67-73 volume:48 year:2005 number:2 pages:67-73 |
sourceStr |
In Acta Medica 48(2005), 2, Seite 67-73 volume:48 year:2005 number:2 pages:67-73 |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
Endothelin Endothelin receptor Endothelin receptor agonist Endothelin receptor antagonist Bosentan Pulmonary hypertension treatment Medicine R |
isfreeaccess_bool |
true |
container_title |
Acta Medica |
authorswithroles_txt_mv |
Jiří Patočka @@aut@@ Vladimír Měrka @@aut@@ Vratislav Hrdina @@aut@@ Radomír Hrdina @@aut@@ |
publishDateDaySort_date |
2005-01-01T00:00:00Z |
hierarchy_top_id |
320418170 |
id |
DOAJ039212548 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ039212548</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230308030026.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2005 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.14712/18059694.2018.34</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ039212548</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJe6114750a1dc45e2b0ef522e39c826f7</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Jiří Patočka</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Pharmacological Potential of Endothelin Receptors Agonists and Antagonists</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2005</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Endothelins are potent predominantly vasoconstricting agents that act as local autocrine and paracrine mediators. Endothelin-1 is the most potent and sustained vasoconstrictor and pressor substance yet identified. Abnormalities of the endothelin system occur in a range of diseases associated with vasoconstriction, vasospasm, and vascular hypertrophy. ET receptor antagonists were until recently regarded as drugs of great promise in patients with congestive heart failure, pulmonary hypertension and others. The aim of this article is a survey of compounds that affect the endothelin receptors and clinical trials with these agents.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Endothelin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Endothelin receptor</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Endothelin receptor agonist</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Endothelin receptor antagonist</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Bosentan</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pulmonary hypertension treatment</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Vladimír Měrka</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Vratislav Hrdina</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Radomír Hrdina</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Acta Medica</subfield><subfield code="d">Karolinum Press, 2004</subfield><subfield code="g">48(2005), 2, Seite 67-73</subfield><subfield code="w">(DE-627)320418170</subfield><subfield code="w">(DE-600)2002210-4</subfield><subfield code="x">18059694</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:48</subfield><subfield code="g">year:2005</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:67-73</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.14712/18059694.2018.34</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/e6114750a1dc45e2b0ef522e39c826f7</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://actamedica.lfhk.cuni.cz/48/2/0067/</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1211-4286</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1805-9694</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">48</subfield><subfield code="j">2005</subfield><subfield code="e">2</subfield><subfield code="h">67-73</subfield></datafield></record></collection>
|
author |
Jiří Patočka |
spellingShingle |
Jiří Patočka misc Endothelin misc Endothelin receptor misc Endothelin receptor agonist misc Endothelin receptor antagonist misc Bosentan misc Pulmonary hypertension treatment misc Medicine misc R Pharmacological Potential of Endothelin Receptors Agonists and Antagonists |
authorStr |
Jiří Patočka |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)320418170 |
format |
electronic Article |
delete_txt_mv |
keep |
author_role |
aut aut aut aut |
collection |
DOAJ |
remote_str |
true |
illustrated |
Not Illustrated |
issn |
18059694 |
topic_title |
Pharmacological Potential of Endothelin Receptors Agonists and Antagonists Endothelin Endothelin receptor Endothelin receptor agonist Endothelin receptor antagonist Bosentan Pulmonary hypertension treatment |
topic |
misc Endothelin misc Endothelin receptor misc Endothelin receptor agonist misc Endothelin receptor antagonist misc Bosentan misc Pulmonary hypertension treatment misc Medicine misc R |
topic_unstemmed |
misc Endothelin misc Endothelin receptor misc Endothelin receptor agonist misc Endothelin receptor antagonist misc Bosentan misc Pulmonary hypertension treatment misc Medicine misc R |
topic_browse |
misc Endothelin misc Endothelin receptor misc Endothelin receptor agonist misc Endothelin receptor antagonist misc Bosentan misc Pulmonary hypertension treatment misc Medicine misc R |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
hierarchy_parent_title |
Acta Medica |
hierarchy_parent_id |
320418170 |
hierarchy_top_title |
Acta Medica |
isfreeaccess_txt |
true |
familylinks_str_mv |
(DE-627)320418170 (DE-600)2002210-4 |
title |
Pharmacological Potential of Endothelin Receptors Agonists and Antagonists |
ctrlnum |
(DE-627)DOAJ039212548 (DE-599)DOAJe6114750a1dc45e2b0ef522e39c826f7 |
title_full |
Pharmacological Potential of Endothelin Receptors Agonists and Antagonists |
author_sort |
Jiří Patočka |
journal |
Acta Medica |
journalStr |
Acta Medica |
lang_code |
eng |
isOA_bool |
true |
recordtype |
marc |
publishDateSort |
2005 |
contenttype_str_mv |
txt |
container_start_page |
67 |
author_browse |
Jiří Patočka Vladimír Měrka Vratislav Hrdina Radomír Hrdina |
container_volume |
48 |
format_se |
Elektronische Aufsätze |
author-letter |
Jiří Patočka |
doi_str_mv |
10.14712/18059694.2018.34 |
author2-role |
verfasserin |
title_sort |
pharmacological potential of endothelin receptors agonists and antagonists |
title_auth |
Pharmacological Potential of Endothelin Receptors Agonists and Antagonists |
abstract |
Endothelins are potent predominantly vasoconstricting agents that act as local autocrine and paracrine mediators. Endothelin-1 is the most potent and sustained vasoconstrictor and pressor substance yet identified. Abnormalities of the endothelin system occur in a range of diseases associated with vasoconstriction, vasospasm, and vascular hypertrophy. ET receptor antagonists were until recently regarded as drugs of great promise in patients with congestive heart failure, pulmonary hypertension and others. The aim of this article is a survey of compounds that affect the endothelin receptors and clinical trials with these agents. |
abstractGer |
Endothelins are potent predominantly vasoconstricting agents that act as local autocrine and paracrine mediators. Endothelin-1 is the most potent and sustained vasoconstrictor and pressor substance yet identified. Abnormalities of the endothelin system occur in a range of diseases associated with vasoconstriction, vasospasm, and vascular hypertrophy. ET receptor antagonists were until recently regarded as drugs of great promise in patients with congestive heart failure, pulmonary hypertension and others. The aim of this article is a survey of compounds that affect the endothelin receptors and clinical trials with these agents. |
abstract_unstemmed |
Endothelins are potent predominantly vasoconstricting agents that act as local autocrine and paracrine mediators. Endothelin-1 is the most potent and sustained vasoconstrictor and pressor substance yet identified. Abnormalities of the endothelin system occur in a range of diseases associated with vasoconstriction, vasospasm, and vascular hypertrophy. ET receptor antagonists were until recently regarded as drugs of great promise in patients with congestive heart failure, pulmonary hypertension and others. The aim of this article is a survey of compounds that affect the endothelin receptors and clinical trials with these agents. |
collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 |
container_issue |
2 |
title_short |
Pharmacological Potential of Endothelin Receptors Agonists and Antagonists |
url |
https://doi.org/10.14712/18059694.2018.34 https://doaj.org/article/e6114750a1dc45e2b0ef522e39c826f7 https://actamedica.lfhk.cuni.cz/48/2/0067/ https://doaj.org/toc/1211-4286 https://doaj.org/toc/1805-9694 |
remote_bool |
true |
author2 |
Vladimír Měrka Vratislav Hrdina Radomír Hrdina |
author2Str |
Vladimír Měrka Vratislav Hrdina Radomír Hrdina |
ppnlink |
320418170 |
mediatype_str_mv |
c |
isOA_txt |
true |
hochschulschrift_bool |
false |
doi_str |
10.14712/18059694.2018.34 |
up_date |
2024-07-03T22:13:27.667Z |
_version_ |
1803597704246329344 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ039212548</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230308030026.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2005 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.14712/18059694.2018.34</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ039212548</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJe6114750a1dc45e2b0ef522e39c826f7</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Jiří Patočka</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Pharmacological Potential of Endothelin Receptors Agonists and Antagonists</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2005</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Endothelins are potent predominantly vasoconstricting agents that act as local autocrine and paracrine mediators. Endothelin-1 is the most potent and sustained vasoconstrictor and pressor substance yet identified. Abnormalities of the endothelin system occur in a range of diseases associated with vasoconstriction, vasospasm, and vascular hypertrophy. ET receptor antagonists were until recently regarded as drugs of great promise in patients with congestive heart failure, pulmonary hypertension and others. The aim of this article is a survey of compounds that affect the endothelin receptors and clinical trials with these agents.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Endothelin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Endothelin receptor</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Endothelin receptor agonist</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Endothelin receptor antagonist</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Bosentan</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pulmonary hypertension treatment</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Vladimír Měrka</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Vratislav Hrdina</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Radomír Hrdina</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Acta Medica</subfield><subfield code="d">Karolinum Press, 2004</subfield><subfield code="g">48(2005), 2, Seite 67-73</subfield><subfield code="w">(DE-627)320418170</subfield><subfield code="w">(DE-600)2002210-4</subfield><subfield code="x">18059694</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:48</subfield><subfield code="g">year:2005</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:67-73</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.14712/18059694.2018.34</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/e6114750a1dc45e2b0ef522e39c826f7</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://actamedica.lfhk.cuni.cz/48/2/0067/</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1211-4286</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1805-9694</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">48</subfield><subfield code="j">2005</subfield><subfield code="e">2</subfield><subfield code="h">67-73</subfield></datafield></record></collection>
|
score |
7.3999805 |